Skip to main content
Vai all'homepage della Commissione europea (si apre in una nuova finestra)
italiano it
CORDIS - Risultati della ricerca dell’UE
CORDIS

Kits for advanced polymer-lipid nanocarriers for targeted delivery of RNAs to cardiac and skeletal muscle cells

Descrizione del progetto

Progredire nella somministrazione di RNA terapeutici al tessuto muscolare

I farmaci a base di RNA sfruttano la potenza delle molecole di RNA, come gli RNA interferenti brevi (siRNA) e gli RNA messaggeri (mRNA), per indirizzare e modulare geni specifici. Nonostante il loro grande potenziale, il loro utilizzo è stato limitato al trattamento delle malattie del fegato e ai vaccini contro la COVID-19, soprattutto a causa della mancanza di veicoli di somministrazione efficienti. Finanziato dal Consiglio europeo della ricerca, il progetto POLIRNA mira a sviluppare nanocarrier a base lipidica non tossici, formulati per la somministrazione efficiente di RNA terapeutico ai cardiomiociti e alle cellule muscolari scheletriche. La collaborazione con esperti e il supporto dell’industria faciliteranno la convalida della tecnologia e potenzialmente porteranno a una start-up e a opportunità di investimento.

Obiettivo

Currently, RNA therapies are available on the clinics to treat liver diseases and as COVID-19 vaccines. Hence, their therapeutic potential still remains largely unexploited for the treatment of other disorders, such as age-related, rare genetic and infectious diseases. One key problem for effective preclinical research on new RNA therapies is the lack of safe, efficient and cell-specific delivery vehicles. Gold-standard cationic lipid transfection reagents suffer from dose-dependent cytotoxicity, inability for cell-targeted delivery and poor stability. Clinically approved lipid nanoparticles efficiently target liver cells, while attempts to target other cell types have achieved limited success. In POLIRNA I will develop and validate a new safe, efficient, and versatile platform for RNA release to target multiple cell types, based on ligand-functionalized polymer-lipid nanocarriers, by exploiting a new patented method from my ERC-funded project BIORECAR (772168). POLIRNA consists of “kits for research use”, allowing user-friendly preparation of nanocarriers able to effectively deliver non-coding RNAs (such as siRNAs and microRNAs) to target cardiomyocytes and skeletal muscle cells for preclinical research studies on cardiac regenerative medicine and muscle-related diseases (e.g. neuromuscular diseases). Technology development and validation will benefit from collaboration with major experts in the fields and companies supporting the innovation route from lab-to-market. My previous experience as coordinator of research and innovation projects and as co-founding member of an academic spin-off company, and the current involvement of my team in business plan competitions will drive the process of technology validation, with the aim to strengthen technology value proposition versus current gold-standard solutions, found a start-up company and attract investments.

Campo scientifico (EuroSciVoc)

Programma(i)

Argomento(i)

Meccanismo di finanziamento

HORIZON-ERC-POC - HORIZON ERC Proof of Concept Grants

Vedi tutti i progetti finanziati nell’ambito di questo schema di finanziamento

Invito a presentare proposte

(si apre in una nuova finestra) ERC-2022-POC2

Vedi tutti i progetti finanziati nell’ambito del bando

Istituzione ospitante

POLITECNICO DI TORINO
Contributo netto dell'UE
€ 150 000,00
Indirizzo
CORSO DUCA DEGLI ABRUZZI 24
10129 Torino
Italia
Regione
Nord-Ovest Piemonte Torino
Tipo di attività
Higher or Secondary Education Establishments
Collegamenti
Costo totale
Nessun dato

Beneficiari (1)